October 17,Boston, Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD) drugs, announced that it has entered into a strategic collaboration and licensing agreement with Roche to discover and develop therapies targetingPreviously considered undruggableTargets for Cancer and Neurological DiseasesNovel Molecular GlueAntidote。
Monte Rosa to Receive $50 Million Upfront Payment and is Eligible for Future Potential Payments Exceeding $2 Billion in Preclinical, Clinical, Commercial, and Sales Milestones, as Well as Tiered Royalties. Both Parties Have Agreed on a Mechanism to Expand Collaboration Across Multiple Targets Within the First Two Years. In This Context, Additional Payments for Nominations, Preclinical, Clinical, Commercial, and Sales Milestones, as Well as Tiered Royalties for Resulting Products, Will Be Due. Monte Rosa Will Advance Discovery and Preclinical Activities for Multiple Selected Cancer and Neurological Disease Targets to a Defined Point. Roche Has Secured Rights for Further Preclinical and Clinical Development of the Compound.Monte RosaRetain full ownership of its pipeline projects.
Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics, stated:"We are thrilled to partner with Roche, one of the leading healthcare and top-tier oncology companies globally. Our QuEEN™ discovery engine is a highly validated, industry-leading molecular glue degrader platform, serving as the cornerstone of Monte Rosa's success and driving our carefully selected..."Molecular Glue DegradersThe discovery and successful development have entered clinical trials. This collaboration will enable our platform to accelerate its expansion into other areas of neuroscience and oncology. We believe that our decision to partner with Roche,Roche"With a shared vision and drive, we will expand our collective strengths and capabilities, accelerating the development of transformative treatments for patients across multiple indications."
Global Head of Collaboration at Roche PharmaceuticalsDr. James Sabry said:"We believe that molecular glue degraders are a powerful new class of small molecules that target disease-related proteins which traditional methods cannot address. We look forward to working with Monte Rosa Therapeutics to tackle high-value targets in oncology and neuroscience, unlocking new therapeutic possibilities."Follow the official account below to see the world!
